UOC
BCYC

UBS O'Connor’s Bicycle Therapeutics BCYC Stock Holding History

UBS O'Connor’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,000
Closed -$11.3K – 303
2025
Q2 		$11.3K Buy
+50,000
New +$398K ﹤0.01% 350
2024
Q4 		– Sell
-20,000
Closed -$10.5K – 443
2024
Q3 		$10.5K Buy
+20,000
New +$461K ﹤0.01% 462
2024
Q2 		– Sell
-70,000
Closed -$130K – 552
2024
Q1 		$130K Sell
70,000
-55,000
-44% -$1.17M ﹤0.01% 415
2023
Q4 		$226K Buy
125,000
+101,500
+432% +$1.68M 0.01% 396
2023
Q3 		$52.3K Buy
+23,500
New +$537K ﹤0.01% 487

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

UBS O'Connor's BCYC Position: Q3 2025 in Review

UBS O'Connor sold out of Bicycle Therapeutics (BCYC) in Q3 2025, closing a stake of 143,800 shares — an estimated $999K sold.

UBS O'Connor first reported a position in BCYC in Q1 2022 and held it in 14 quarters. The position peaked at $2.38M in Q4 2022. 99 funds tracked by Wall St. Rank hold BCYC as of Q3 2025.

  • UBS O'Connor reported no remaining Bicycle Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 143,800 Bicycle Therapeutics shares in Q3 2025, an estimated $999K.
  • UBS O'Connor first reported a position in Bicycle Therapeutics in Q1 2022 and held it in 14 quarters.
  • UBS O'Connor's Bicycle Therapeutics position peaked at $2.38M in Q4 2022.
  • 99 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.